$IMGN to; Discontinue the development of IMGN779 in adults with relapsedrefractory CD33positive AML;Suspend all other research activities;Reduce its workforce by approximately 220 employees

$IMGN to; Discontinue the development of IMGN779 in adults with relapsed/refractory CD33-positive AML; Suspend all other research activities; Reduce its workforce by approximately 220 employees

$IMGN to; Discontinue the development of IMGN779 in adults with relapsed/refractory CD33-positive AML; Suspend all other research activities; Reduce its workforce by approximately 220 employees

More From BioPortfolio on "$IMGN to; Discontinue the development of IMGN779 in adults with relapsed/refractory CD33-positive AML; Suspend all other research activities; Reduce its workforce by approximately 220 employees"